Mechanistic Insights into Off-the-Shelf vs. Personalized mRNA Cancer Vaccines: A Comparative Review of BNT111 and BNT122
Authors:
- Cheska Jane A. CudogCheska Jane A. Cudog
- Trisha Anne A. ArcillaTATrisha Anne A. Arcilla
- Angel Mae D. GregorioAGAngel Mae D. Gregorio
- Samantha D. RamosSRSamantha D. Ramos
- Eunice S. SalazarESEunice S. Salazar
- Jenny L. SindinganJSJenny L. Sindingan
- Marianne Joy L. TubalinalMTMarianne Joy L. Tubalinal
- Huai-Ying HuangHHHuai-Ying Huang
- Po-Hua WuPWPo-Hua Wu
- Hoang MinhHMHoang Minh
- Kuo-Pin ChuangKCKuo-Pin Chuang
- Brian Harvey Avanceña VillanuevaBrian Harvey Avanceña Villanueva
Open Access
Abstract
MRNA vaccines are a relevant approach in cancer immunotherapy, using messenger RNA to induce immune responses against tumor-associated antigens. In this review, BNT111 and BNT122 are compared as representative off-the-shelf and personalized models. BNT111 is a fixed mRNA vaccine that has demonstrated significant antitumor efficacy against shared melanoma antigens, particularly when combined with immune checkpoint inhibitors. It allows a standardized production via in vitro transcription (IVT) in a cell-free system. Conversely, BNT122 is a personalized vaccine designed to match an individual’s tumor mutations by targeting patient-specific neoantigens to elicit more robust immune responses. It has significant suitability in the adjuvant setting to target minimal residual disease. Despite favorable safety and immunogenicity, the effectiveness of these vaccines is influenced by various factors, including tumor heterogeneity, differences in antigen expression, off-target effects on mRNA-LNP distribution, molecular instability, and complex manufacturing constraints. Neither approach can be directly considered as the definitive optimal vaccine. A comprehensive analysis of their strengths and limitations is vital for a balanced and objective future research direction. Collectively, this emphasizes the need for further improvements in vaccine design and strategies, prioritizing high-quality, safe, and accessible treatments for every cancer-based patient and ensuring their successful integration into healthcare.Keywords
This publication has 87 references indexed in Scilit:
- mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology TherapeuticsCancer Innovation, 2025
- mRNA Vaccines in Cancer Immunotherapy: Recent Advances, Clinical Translation, and Future PerspectivesCurrent Medical Science, 2025
- Extracellular Vesicle‐Based mRNA Therapeutics and VaccinesExploration, 2025
- mRNA vaccines and SiRNAs targeting cancer immunotherapy: challenges and opportunitiesDiscover Oncology, 2025
- Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control studyVirchows Archiv, 2024
- Overexpression of Transmembrane Phosphatase with Tensin homology (TPTE) in prostate cancer is clinically significant, suggesting its potential as a valuable biomarkerJournal of Cancer Research and Clinical Oncology, 2024
- mRNA vaccine in cancer therapy: Current advance and future outlookClinical and Translational Medicine, 2023
- mRNA: A promising platform for cancer immunotherapyAdvanced Drug Delivery Reviews, 2023
- Bioengineering of Novel Non-Replicating mRNA (NRM) and Self-Amplifying mRNA (SAM) Vaccine Candidates Against SARS-CoV-2 Using Immunoinformatics ApproachMolecular Biotechnology, 2022
- Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancerCellular Oncology, 2016